DRIO (36) NEPH (73) CVRX (43) XTNT (69) ⌘ Pro Terminal →

Heartbeam Inc. (BEAT) — RQD Stock Rating Cockpit

$0.54 +1.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.54

Heartbeam Inc. (BEAT) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $30.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.54 (+0.05%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BEAT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY BEAT SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (26% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 63.4 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.48-8.3% Next Q

Q2 (-2Q)

Grade D$0.44-11.4% Next Q

Q3 (-1Q)

Grade D$0.39+38.5% Next Q

Current

Grade D$0.54-1.4% Hist 90D α

Trajectory: D (42) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BEAT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BEAT currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.44) and Max Pain ($0.57) forces dealer call-delta covering toward $4.20.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BEAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BEAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

63.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE5% OF RANGE

L: $0$0.54H: $4

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on BEAT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

20/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like BEAT

✓Big institutional funds and options desks are actively positioning on the bullish side.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BEAT)

✓Walkthrough of BEAT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BEAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.21%📐 HORIZONTAL RANGE

2026-10-30O $0.54H $0.56L $0.52C $0.54VOL 1.57M

RES: $0.95SUP: $0.27SMA50: $0.44SMA200: $0.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BEAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BEAT Butterfly Map → + Track BEAT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BEAT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BEAT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BEAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BEAT)

Health Care Rank #352 of 1016 ⚔️ DRIO vs BEAT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BEAT vs. DRIO, NEPH, CVRX, XTNT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Heartbeam Inc. (BEAT) ranks #352 by composite RQD confidence (50/100, grade D) and #803 by equity capitalization ($30.4M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with BEAT at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BEAT ACTIVE Heartbeam Inc.	D	50/100	—	—	-35.0%	+1.34%	$30.4M	Benchmark Subject
DRIO DarioHealth Corp.	D-	36/100	—	56.6%	-35.0%	-2.93%	$32.4M	/drio-vs-beat →
NEPH Nephros Inc.	B	73/100	29.8x	61.9%	18.9%	+3.16%	$35.5M	/neph-vs-beat →
CVRX CVRx Inc.	D-	43/100	—	85.3%	-35.0%	+1.79%	$38.0M	/cvrx-vs-beat →
XTNT Xtant Medical Holdings Inc.	C+	69/100	—	62.9%	12.8%	+1.54%	$40.7M	/xtnt-vs-beat →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001779372

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Heartbeam Inc. (BEAT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$21.0M, operating cash flow of -$14.0M, and free cash flow of -$14.6M (+0.6% YoY). On the balance sheet, BEAT closed FY2025 with $5.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$21.0M	-$14.0M	-$14.6M	$5.8M	—
FY2024 (FY)	2024-12-31	$0	-$19.4M	-$14.5M	-$14.7M	$3.3M	—
FY2023 (FY)	2023-12-31	$0	-$14.6M	-$12.1M	-$12.1M	—	—

3. BEAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BEAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Heartbeam Inc. (NASDAQ: BEAT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.54 (+1.34% 1D, market cap $30.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BEAT ranks #352 in composite RQD confidence.

How does BEAT compare to DRIO and NEPH in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BEAT carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DRIO (DarioHealth Corp.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M) and NEPH (Nephros Inc.) posts a B grade (73/100 RQD, P/E 29.8x, ROIC 18.9%, cap $35.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BEAT?

Per BEAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779372), Heartbeam Inc. generated $0 in revenue, -$21.0M in net income, and -$14.6M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BEAT trading relative to its 50-day, 200-day, and 52-week technical levels?

BEAT last traded at $0.54 (+1.34% on volume of 2,476,521 shares), positioning the stock +22.73% above its 50-day simple moving average ($0.44) and -37.21% below its 200-day simple moving average ($0.86). Across its 52-week range of $0.36 to $4.00, BEAT sits at the 4.9% percentile with a 14-day RSI of 63.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.00 to $0.61).

BEAT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell BEAT stock right now?

Heartbeam Inc. (BEAT) currently earns a Roarable Rating of D (Sell — SELL) with 50/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is BEAT's 12-month price target and RQD AI Jury consensus?

BEAT's 12-month base price target is $0.52 (range $0.41 to $4.2), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: BEAT RQD Cockpit BEAT 12M Forecast BEAT Earnings & Move BEAT Dividends & DRIP BEAT Insiders & 13F BEAT Whale Options BEAT Profit Sankey BEAT News & Why